

JSA Best Presentation Award 2012

Factors Contributing to an Accelerated Decline in Pulmonary Function in Asthma

Yoshihiro Kanemitsu¹, Hisako Matsumoto¹, Michiaki Mishima¹ and the KiHAC Respiratory Medicine Group

ABSTRACT

Patients with asthma show a steeper age-related decline in pulmonary function than healthy subjects, which is often alleviated after the initiation of treatment with inhaled corticosteroids (ICS). However, there still are patients who develop irreversible airflow limitations despite receiving adequate ICS treatment. The identification of the characteristics of such patients and biomarkers of progression for airflow limitation, a functional consequence of airway remodeling, is considered important in the management of asthma.

A variety of biomarkers are associated with the forced expiratory volume in 1 s (FEV₁) in asthma in a cross-sectional fashion. However, few biomarkers are known to reflect the decline in pulmonary function, particularly in patients with asthma who receive ICS treatment. Recently periostin, a matricellular protein that prolongs Th2/eosinophilic inflammation and reflects airway remodeling, was reported to be detected in serum. In a Kinki Hokuriku Airway disease Conference multicenter cohort study, we demonstrated that among several serum markers, high serum periostin level, particularly ≥ 95 ng/mL, was the only marker associated with a greater annual decline in FEV₁ and a decline in FEV₁ of ≥ 30 mL·yr⁻¹. A variant (rs9603226) of the *POSTN* gene that encodes periostin was also involved in the frequency of a decline in FEV₁ of ≥ 30 mL·yr⁻¹.

Our results suggest that the serum periostin level is a useful marker reflecting pulmonary function decline in patients with asthma receiving ICS.

KEY WORDS

asthma, biomarker, inhaled corticosteroids, periostin, pulmonary function decline

INTRODUCTION

Asthma is a chronic inflammatory disorder of the airways characterized by the infiltration of various inflammatory cells, cytokines, and mediators, all of which contribute to the development of airway hyper-responsiveness (AHR), remodeling,¹ and the progression of airflow limitation,² a functional consequence of airway remodeling. As a result of inhaled corticosteroids (ICS), the mainstay of asthma treatment, airway inflammation³ and AHR³ have been well controlled, which then prevents the progression of irreversible airflow limitations.⁴⁻⁷ However, some patients

with asthma still develop fixed airflow limitations despite intensive treatment. Indeed, short-term treatment with ICS has been shown to significantly decrease airway wall thickening on computed tomography,⁸ whereas long-term treatment with ICS may not consistently reverse the changes in the remodeled airways.⁹ These findings suggest that the response to long-term treatment with ICS may be heterogeneous among asthmatic patients, which may relate to insensitivity to ICS. Clarifying the background of asthmatics with progressive airflow limitation would be important by itself¹⁰ and also for providing clues about ways to overcome insensitivity to ICS treatment.

¹Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Conflict of interest: No potential conflict of interest was disclosed.

Correspondence: Hisako Matsumoto, MD, PhD, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Ja-

pan.

Email: hmatsumo@kuhp.kyoto-u.ac.jp

Received 27 November 2013. Accepted for publication 1 January 2014.

©2014 Japanese Society of Allergy

Our study group and others have demonstrated a variety of biomarkers useful in the understanding of asthma pathogenesis.¹¹⁻²³ Those include markers in the sputum supernatant,¹¹⁻¹⁹ exhaled air,^{20,21} and blood.^{22,23} However, there have been a limited number of biomarkers that could be applicable in actual clinical settings, as mentioned in the recent statement from the National Institutes of Health.²⁴ The development of such clinically applicable biomarkers is thus warranted for better asthma management.

In this review article, we summarize the factors that are associated with a decline in pulmonary function. The effects of ICS treatment are also presented. We show the role of the serum periostin level as a biomarker that reflects refractory Th2/eosinophilic inflammation and pulmonary function decline in patients with asthma who receive ICS.

RISK FACTORS OF PULMONARY FUNCTION DECLINE

Pulmonary function reaches a maximum in the early twenties and starts to decline from around the age 25.²⁵ The earlier studies on the contributing factors for a decline in pulmonary function demonstrated that the recent onset of asthma, frequent asthma symptoms and severe exacerbations, AHR, and smoking history could be risk factors for the decline. Blood and sputum eosinophilia and genetic predisposition also influenced the accelerated decline in pulmonary function in patients with asthma (Table 1). In the following paragraphs, details on these contributing factors are described. It should be noted, however, that few of the studies addressed whether studied patients had been consistently treated with ICS during the observation periods.

RECENT ONSET OF ASTHMA AND LONG-STANDING ASTHMA

The recent onset of asthma appears to have a negative impact on pulmonary function. A 5-year follow-up survey of the Copenhagen City Heart Study²⁶ and another longitudinal study²⁷ both revealed that adults who newly developed asthma showed an accelerated decline in FEV₁, whereas those who had already been diagnosed as having asthma showed a similar degree of decline in FEV₁ to that of nonasthmatic subjects^{26,27}. A subsequent study showed that patients with disease duration of <15 years showed a steeper decline in FEV₁ than those with a longer disease duration.²⁸ In this analysis, baseline FEV₁ was unrelated to disease duration.²⁸

On the other hand, long-standing asthma is also an important factor for the development of airflow limitation in patients with asthma, particularly in patients with severe asthma receiving maximal treatment, including systemic corticosteroids. The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study (TENOR study) showed that

60% of people with severe or difficult-to-treat asthma had persistent airflow limitation as defined by post-bronchodilator FEV₁/FVC of ≤ 0.7 at two consecutive annual visits. This study also revealed that longer disease duration was one of the risk factors that was associated with persistent airflow limitation.²⁹ Another cross-sectional study that compared younger patients and elderly patients with early-onset or late-onset asthma found that elderly patients who had early-onset asthma had the most severe airway obstruction.³⁰ These findings suggest that long-standing asthma may be also involved in a progressive loss of pulmonary function.^{29,30}

SEVERITY OF ASTHMA

AHR, one of the hallmarks of asthma, is associated with not only asthma symptoms, such as wheezing³¹ and dyspnea,³² but also impaired pulmonary function growth³³ and pulmonary function decline.^{34,35} In an 18-year follow-up study, Peat *et al.* demonstrated that AHR to histamine measured at the end of their study period was associated with accelerated annual decline in FEV₁ in patients with asthma.³⁴ A subsequent study revealed that AHR had a marked influence on the annual decline in FEV₁ in atopic patients but not in nonatopic patients.³⁵ An epidemiological study of a Dutch cohort revealed that AHR was independently associated with an accelerated decline in FEV₁, irrespective of gender, smoking status, age, respiratory symptoms, and baseline FEV₁ levels.³⁶

In addition, persistent symptoms may be a predictive factor for irreversible airflow limitation and accelerated pulmonary function decline in patients with severe asthma refractory to corticosteroid therapy. Among the many symptoms of asthma such as sputum production, cough, wheezing, and dyspnea, an association has been reported between chronic mucus hypersecretion and an accelerated decline in FEV₁ in nonsmoking patients with asthma.^{2,26,37}

Initial increased airway reversibility to short-acting β_2 agonists and long-term treatment with oral corticosteroids were also risk factors for the development of irreversible airflow obstruction.³⁸ A 10-year follow-up survey was conducted to evaluate the frequency of irreversible airway obstruction in life-long nonsmoking adults with long-standing moderate to severe asthma; the mean age was 37 years, mean disease duration at enrollment was 16 years, and 72% patients took ICS. At the end of the study, 23% of the studied patients fulfilled the criteria for irreversible airflow obstruction and showed a greater decline in FEV₁ than patients with reversible airflow obstruction.³⁸

Two recent studies, a historical cohort³⁹ and a prospective cohort,⁴⁰ showed that severe asthma exacerbation may result in an accelerated loss of pulmonary function. In patients with moderate to severe asthma who underwent a 11-year follow-up, those who frequently experienced asthma exacerbations (>0.10 ex-

Table 1 Risk factors for pulmonary function decline in patients with asthma

Major risk factors	Authors, Published year	Follow-up period (years)	n (asthma)	Disease duration (years)	Measurements of FEV ₁ (per individual)	Specific factors associated with pulmonary function decline in FEV ₁
Recent onset of asthma/long-standing asthma	Ulrik <i>et al.</i> 1994 ²⁶	5	10952 (396)	Data not shown	2	Age at disease onset (>20 years), Chronic mucus secretion
	Burrows <i>et al.</i> 1991 ²⁷	13.1	1185 (40)	9.3	7.4	Age at disease onset (>60 years)
	Cibella <i>et al.</i> 2002 ²⁸	5	142 (142)	5.5 (males), 8.8 (females)	10	Disease duration (<15 years), Reversibility (≥15%), Young males
Severity of asthma/symptoms	Peat <i>et al.</i> 1987 ³⁴	18	278 (92)	Data not shown	4-7	Airway hyperresponsiveness
	van Schayck <i>et al.</i> 1991 ³⁵	2	71 (71)	Data not shown	6	Airway hyperresponsiveness in atopic patients
	Lange <i>et al.</i> 1998 ²	15	17506 (1095)	Data not shown	3	Chronic mucus secretion, Smoking
	Postma <i>et al.</i> 1995 ³⁷	13	1439 (231)	Data not shown	Maximal 8	Chronic mucus secretion, Reversibility (≥25%)
	Bai <i>et al.</i> 2007 ³⁹	11	93 (93)	Data not shown	20.8	Severe exacerbation
Smoking	O'Byrne <i>et al.</i> 2009 ⁴⁰	3	315 (315)	0-2	14	Severe exacerbation
	Apostol <i>et al.</i> 2002 ²⁵	10	5057 (613)	Data not shown	4	Smoking
	James <i>et al.</i> 2005 ⁴³	29	9317 (1301)	Data not shown	Maximal 7	Smoking
Inflammation	Broekema <i>et al.</i> 2010 ¹⁸	5-14	47 (47)	Data not shown	2	Sputum eosinophils, Sputum eosinophil cationic protein
	van Veen <i>et al.</i> 2008 ^{† 21}	5.7	98 (98)	18.5	2	Exhaled nitric oxide
	van Rensen <i>et al.</i> 2005 ⁴⁶	7.5	32 (32)	Data not shown	2	Bronchial infiltrate of CD8 T lymphocyte
	Pasternack <i>et al.</i> 2005 ⁴⁷	15	245 (83)	15	2	Chronic <i>Chlamydia pneumoniae</i> infection in nonatopic asthmatics
	Kanemitsu <i>et al.</i> 2013 ^{† 60}	8	224 (224)	20.2	16.2	Serum periostin, genetic predisposition (<i>POSTN</i>), Treatment Step 5, ex-smoking (≤10 pack-years)
Genetic predisposition	Jongepier <i>et al.</i> 2004 ⁴⁹	22	152 (152)	Data not shown	29	Genetic predisposition (<i>ADAM33</i>)
	Dijkstra <i>et al.</i> 2006 ⁵⁰	20.1	129 (129)	Data not shown	23 (males) 20 (females)	Genetic predisposition (<i>ESR1</i>)
	Barton <i>et al.</i> 2009 ⁵¹	20.4	2819 (124)	Data not shown	22.5	Genetic predisposition (<i>PLAUR</i>)

[†] All participants took ICS treatment.

acerbations·yr⁻¹) showed greater annual decline in FEV₁ than those with infrequent exacerbations.³⁹ Meanwhile, ICS treatment may repress the frequency of severe exacerbations and the decline in FEV₁ in patients with mild persistent asthma.⁴⁰

SMOKING

Active smoking worsens not only asthma-related symptoms⁴¹ and airway inflammation^{14,42} but also accelerates a decline in pulmonary function in patients with asthma,^{2,25,43} either in synergistic²⁵ or additive ways.⁴³ In the Copenhagen City Heart study, smokers who had asthma had a steeper decline in FEV₁ than nonsmokers with asthma in a 15-year follow-up.²

Subsequently, the Coronary Artery Risk Development In Young Adults study of subjects with the average age of 24.8 at baseline showed that the initiation of smoking or exposure to it before age 15 was associated with a rapid decline in FEV₁ compared with those participants who never smoked or started smoking later.²⁵ Furthermore, the combination of asthma and heavy smoking (≥15 cigarettes per day) had a synergic effect on the rate of decline in FEV₁.²⁵ In the Busselton Health Survey conducted by James *et al.*, where the average baseline age of the participants was 40, showed that asthma and smoking additively contributed to an accelerated decline in FEV₁.⁴³ Lastly, Perret *et al.* showed a synergic interaction be-

Table 2 Effects of polymorphisms on an accelerated decline in FEV₁ in patients with asthma

Authors, Published year	Gene	SNP No.	Location	Allelic	Risk genotype	Decline in FEV ₁ (mL·yr ⁻¹)	Difference compared with major homozygous genotypes (mL·yr ⁻¹)
Jongepier <i>et al.</i> 2004 ⁴⁹	<i>ADAM33</i>	rs528557	3'UTR	G/C-	CC	data not shown	-23.7
Dijkstra <i>et al.</i> 2006 ⁵⁰	<i>ESR1</i>	rs2077647	Exon1	C/T	TC	-23.1	-11.6
					CC	-27.2	-15.7
		rs9340799	Intron1	G/A	AA	-27.6	-16.1
		rs2234693	Intron1	C/T	TT	-29.2	-13.3
		rs9322331	Intron1	T/C	CC	-25.8	-15.2
		rs4870056	Intron1	A/G	GG	-28.4	-13.0
Barton <i>et al.</i> 2009 ⁵¹	<i>PLAUR</i>	rs2356338	5'UTR	G/T	TT	-34.4	-14.6
		rs4251953	3'UTR/Intron	G/A	GA/GG	-37.9	-15.9
		rs4802189	3'UTR	C/A	CA/AA	-32.4	-13.4
		rs4803648	3'UTR	T/A	AA	-36.1	-17.0
					TA/AA	-31.0	-10.8
Kanemitsu <i>et al.</i> 2013 ⁶⁰	<i>POSTN</i>	rs9603226	Intron21	G/A	GA/AA	-11.4	-7.3

tween asthma and active smoking on the development of fixed airway obstruction (post bronchodilator FEV₁/FVC of <0.7),⁴⁴ which was only observed in atopic patients with asthma.

INFLAMMATION

Asthma is classically characterized by Th2 and eosinophilic inflammation. Several cross-sectional studies showed that sputum eosinophilia and increased eosinophil cationic protein levels were independent risk factors for persistent airflow limitation in patients with severe refractory asthma.^{16,17} In a longitudinal study of steroid-naïve patients with asthma, during a mean of 9-year follow-up, Broekema *et al.* demonstrated that a greater annual decline in FEV₁ was associated with a high number of eosinophil in the sputum or high eosinophil cationic protein levels, particularly when patients showed a decline in FEV₁ of ≥30 mL·yr⁻¹.¹⁸ Ulrik also proposed the possibility that higher blood eosinophil counts in childhood asthma were associated with lower predicted FEV₁ in early adulthood in patients with asthma.⁴⁵ In patients with difficult-to-treat asthma, van Veen found that exhaled nitric oxide of ≥20 parts per billion was a predictor of accelerated decline in FEV₁ if their baseline predicted FEV₁ was ≥80%.²¹

Apart from eosinophils, neutrophils and lymphocytes may also be involved in impaired pulmonary function.^{19,46} Shaw *et al.*, in a cross-sectional study, showed that increased sputum neutrophil counts were associated with lower %FEV₁.¹⁹ Thereafter, we found negative correlation between pulmonary function and the sputum levels of YKL-40 that was mostly expressed in sputum neutrophils and macrophages.¹³ In one study with 7.5-year follow-up, CD8⁺ T lymphocytes in bronchial tissue were solely related to an accelerated decline in FEV₁.⁴⁶ In nonatopic patients with asthma, chronic infection with *Chlamydomphila*

pneumoniae was considered a risk factor for an accelerated decline in FEV₁.⁴⁷

GENETIC PREDISPOSITION

The etiology of asthma is complicated because of its heterogeneity which originates in genetic and environmental interaction and variability. Positional cloning, candidate gene screenings, and genome-wide association (GWA) studies have identified relationships between gene variants (single-nucleotide polymorphisms; SNPs) and susceptibility to asthma. A recent GWA study did not identify any SNPs that contributed to the decline of pulmonary function in adults with asthma.⁴⁸ However, earlier candidate gene screenings that were conducted in a mostly Caucasian population showed associations between pulmonary function decline and several gene variants [SNPs of A disintegrin and metalloproteinase domain 33 (*ADAM33*)⁴⁹, estrogen receptor α (*ESR1*)⁵⁰ and plasminogen activator receptor (*PLAUR*)⁵¹] (Table 1, 2). These associations have been well summarized elsewhere.⁵² In a recent cross-sectional study, SNPs of four genes that are involved in the Th1 or IL-12 cytokine family pathways (*IL12A*, *IL12RB1*, *STAT4*, and *IRF2*) were associated with lower percent predicted FEV₁ and disease severity of asthma.⁵³ The authors proposed a hypothesis of “two-step progression asthma genetic model,” where genes variants in the Th2 pathways confer asthma susceptibility and then variants in the Th1 or IL-12 cytokine family pathways affect the impaired pulmonary function.⁵³

THE EFFECT OF ICS ON THE DECLINE IN PULMONARY FUNCTION

There is increasing evidence that long-term use of ICS yields beneficial effects on the decline in pulmonary function.^{4,7} In the Inhaled Steroids Treatment As Regular Therapy in Early Asthma study, long-term




Fig. 1 Relationship between the serum periostin level and the annual decline in FEV₁.

treatment with ICS for ≥ 3 years decreases the frequency of severe exacerbations,^{40,54} improves asthma control,⁵⁴ and prevents the progression of the decline in FEV₁.⁴ Meanwhile, several studies have indicated that the efficacy of ICS may vary according to gender,⁵ smoking habits,⁵ or serum total IgE levels.⁶ Dijkstra *et al.* demonstrated that only male patients who had smoked < 5 pack-years benefited from intervention with ICS treatment, showing an attenuated FEV₁ decline during a median follow-up of 23 years (-54.4 mL·yr⁻¹ before ICS intervention *vs* -17.7 mL·yr⁻¹ after ICS intervention).⁵ In the European Community Respiratory Health Survey study, with a median follow-up of 9 years, patients with increased serum total IgE levels (> 100 kU/L) who had been treated with ICS for ≥ 4 years showed less decline in FEV₁ than those who did not receive ICS treatment (10.7 mL·yr⁻¹ lower decline than ICS nonusers).⁶ This beneficial effect of ICS was not observed in patients with lower serum total IgE levels.⁶

SERUM PERIOSTIN, A PROMISING BIOMARKER OF PULMONARY FUNCTION DECLINE

Dozens of biomarkers are associated with FEV₁ in a cross-sectional fashion. However, few biomarkers that reflect pulmonary function decline have been identified. Periostin is a matricellular protein, secreted from airway epithelial cells⁵⁵ and lung fibroblasts⁵⁶ in response to IL-4 and IL-13 signaling. It can bind to other extracellular matrix components such as collagens I, III, and V, fibronectin, tenascin-C, and periostin itself.⁵⁶ Periostin gene expression in airway epithelial cells of patients with asthma was upregulated compared with that in healthy subjects⁵⁷ and its levels correlated with the reticular basement membrane thickness.⁵⁵ A postmortem study demonstrated the deposition of periostin on the subepithelial layer of asthmatic airways.⁵⁶ Serum periostin was recently




Fig. 2 †Patients who showed a decline in FEV₁ of ≥ 30 mL·yr⁻¹ were considered rapid decliners.

identified as the best biomarker to reflect persistent airway eosinophilia in patients with severe asthma who were receiving high-dose ICS (≥ 1000 μ g/day)⁵⁸ and also predicted the response to anti-IL-13 antibody treatment.⁵⁹ Collectively, serum periostin may reflect Th2/eosinophilic inflammation and airway remodeling in asthma.

In a multicenter cohort study of Kinki Hokuriku Airway disease Conference (KiHAC), we evaluated the factors associated with an accelerated decline in pulmonary function in 224 asthmatics receiving ICS treatment (average age 62.3 years, 171 females).⁶⁰ In this study, we assessed the annual changes in FEV₁ from at least 1 year after the initiation of ICS treatment to the time of enrollment or later (average, 16.2 measurements over 8 years per individual). Blood granulocyte counts and several serum markers, including serum periostin, high-sensitivity C-reactive protein, and eosinophil cationic protein were examined in association with annual decline in FEV₁. Serum periostin levels were measured using an enzyme-linked immunosorbent assay at Shino-test (Kanagawa, Japan).⁶¹ After the adjustment for several confounding factors, high serum periostin levels, particularly if they were ≥ 95 ng/mL, were solely associated with a greater annual decline in FEV₁ (Fig. 1). This level was determined using the receiver operating characteristic curve analysis with the highest specificity (0.985) from a comparison between 224 patients with asthma (average 92.8 ng/mL) and 66 healthy subjects (average 39.1 ng/mL). Serum periostin levels were positively correlated with the peripheral blood eosinophil counts ($r = 0.30$, $p = 0.0001$), serum eosinophil cationic protein levels ($r = 0.25$, $p = 0.0005$), and serum total IgE levels ($r = 0.29$, $p = 0.0001$). Other independent risk factors for the decline in FEV₁ of ≥ 30 mL·yr⁻¹, i.e., the most intensive treatment step and a history of smoking with light smoking (≤ 10 pack-years) were consistent with previ-

ous findings.^{2,25,43}

On univariate analysis, supplemental findings of the KiHAC cohort study identified risk factors for a greater decline in FEV₁ such as incomplete adherence to medications,⁶² lower Asthma control test[®] scores,⁶³ and comorbidity with or history of sinusitis⁶⁴ and diabetes mellitus.⁶⁵ These findings are also in agreement with previous studies: (1) Shirai *et al.* demonstrated weak associations between a low Asthma control test[®] score and impaired pulmonary function (low %FEV₁ and %PEF),⁶³ (2) chronic sinusitis, one of the common comorbidities of asthma, is related to frequent asthma exacerbations⁶⁶ and decline in pulmonary function,⁶⁴ and (3) patients with type 2 diabetes mellitus with poor glycemic control is associated with the impaired pulmonary function.⁶⁵

Lastly, a polymorphism of the *POSTN* gene, which encodes periostin, was also associated with an accelerated decline in pulmonary function in univariate analysis.⁶⁰ Patients with the AA/AG genotypes of rs9603226 that is located at intron 21 showed a higher frequency of a decline in ≥ 30 mL than those with the GG genotype (30% vs 16%) ($p = 0.02$). In patients who had high serum periostin levels (≥ 95 ng/mL), the frequency of rapid decliners was greater in patients with of the AA/AG genotypes of rs9603226 than in those with the GG genotype (45% vs 19%) ($p = 0.01$) (Table 2, Fig. 2).

CONCLUSION

Even in patients receiving long-term ICS treatment, a history of smoking, albeit with a light smoking history, and the most intensive treatment step remained characteristics of the rapid decliners, which was in line with the findings of the earlier studies. Independent from these clinical characteristics, high serum periostin, a marker of refractory Th2/eosinophilic inflammation, was identified as a novel biomarker reflecting an accelerated decline in FEV₁ in patients with asthma receiving ICS treatment. Targeting refractory Th2/eosinophilic inflammation using serum periostin might yield better outcomes in asthma management.

ACKNOWLEDGEMENTS

We thank Drs. Kenji Izuhara (Saga Medical School), Shoichiro Ohta (Saga Medical School), and Junya Ono (Shino test) for the measurement of serum periostin levels and fruitful discussion on periostin; participants of the project of KiHAC Respiratory Medicine Group, Drs. Yuji Tohda (Kinki University), Hideo Kita (Takatsuki Red Cross Hospital), Takahiko Horiguchi (Fujita Health University Second Educational Hospital), Kazunobu Kuwabara (Fujita Health University Second Educational Hospital), Keisuke Tomii (Kobe City Medical Center General Hospital), Kojiro Otsuka (Kobe City Medical Center General Hospital), Masaki Fujimura (Kanazawa University),

Noriyuki Ohkura (Kanazawa University), Katsuyuki Tomita (Kiniki University), Akihito Yokoyama (Kochi University), Hiroshi Ohnishi (Kochi University), Yasutaka Nakano (Shiga University of Medical Science), Tetsuya Oguma (Shiga University of Medical Science), Soichiro Hozawa (Hiroshima Allergy and Respiratory Clinic), Tadao Nagasaki (Kyoto University), Isao Ito (Kyoto University), Tsuyoshi Oguma (Kyoto University), Hideki Inoue (Kyoto University), Tomoko Tajiri (Kyoto University), Toshiyuki Iwata (Kyoto University), Yumi Izuhara (Kyoto University), and Akio Niimi (Nagoya City University); Drs. Mayumi Tamari (RIKEN), Tomomitsu Hirota (RIKEN), and Tetsuji Yokoyama (National Institute of Public Health) for the fruitful discussion on genetic and statistical analysis.

This study received JSA Best Presentation Award 2012 from the Japanese Society of Allergology.

This study is partly funded by Kinki Hokuriku Airway disease Conference (KiHAC), as a project of KiHAC Respiratory Medicine Group.

REFERENCES

1. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. *J Clin Invest* 1999;**104**:1001-6.
2. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. *N Engl J Med* 1998;**339**:1194-200.
3. Juniper EF, Kline PA, Vanzielegheem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. *Am Rev Respir Dis* 1990;**142**:832-6.
4. O'Byrne PM, Pedersen S, Busse WW *et al.* Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. *Chest* 2006;**129**:1478-85.
5. Dijkstra A, Vonk JM, Jongepier H *et al.* Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. *Thorax* 2006;**61**:105-10.
6. de Marco R, Marcon A, Jarvis D *et al.* Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE. *J Allergy Clin Immunol* 2007;**119**:611-7.
7. Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. *Thorax* 2006;**61**:100-4.
8. Niimi A, Matsumoto H, Amitani R *et al.* Effect of short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. *Am J Med* 2004;**116**:725-31.
9. Matsumoto H, Niimi A, Takemura M *et al.* Long-term changes in airway-wall thickness on computed tomography in asthmatic patients. *J Investig Allergol Clin Immunol* 2011;**21**:113-9.
10. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institute of Health, 2007.
11. Matsumoto H, Niimi A, Takemura M *et al.* Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. *Thorax* 2005;**60**:277-81.
12. Yamaguchi M, Niimi A, Matsumoto H *et al.* Sputum levels

- of transforming growth factor-beta1 in asthma: relation to clinical and computed tomography findings. *J Investig Allergol Clin Immunol* 2008;**18**:202-6.
13. Otsuka K, Matsumoto H, Niimi A *et al*. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. *Respiration* 2012;**83**:507-19.
 14. Nagasaki T, Matsumoto H, Nakaji H *et al*. Smoking attenuates the age-related decrease in IgE levels and maintains eosinophilic inflammation. *Clin Exp Allergy* 2013;**43**: 608-15.
 15. Tajiri T, Matsumoto H, Niimi A *et al*. Association of eosinophilic inflammation with FKBP51 expression in sputum cells in asthma. *PLoS One* 2013;**8**:e65284.
 16. Pizzichini E, Pizzichini MM, Efthimiadis A, Dolovich J, Hargreave FE. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. *J Allergy Clin Immunol* 1997;**99**:539-44.
 17. ten Brinke A, Zwiderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. *Am J Respir Crit Care Med* 2001;**164**: 744-8.
 18. Broekema M, Volbeda F, Timens W *et al*. Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of FEV₁. *Respir Med* 2010;**104**: 1254-62.
 19. Shaw DE, Berry MA, Hargadon B *et al*. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. *Chest* 2007;**132**:1871-5.
 20. Matsumoto H, Niimi A, Jinnai M *et al*. Association of alveolar nitric oxide levels with pulmonary function and its reversibility in stable asthma. *Respiration* 2011;**81**:311-7.
 21. van Veen IH, Ten Brinke A, Sterk PJ *et al*. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. *Eur Respir J* 2008;**32**:344-9.
 22. Matsumoto H, Niimi A, Minakuchi M, Izumi T. Serum eosinophil cationic protein levels measured during exacerbation of asthma: characteristics of patients with low titres. *Clin Exp Allergy* 2001;**31**:637-43.
 23. Takemura M, Matsumoto H, Niimi A *et al*. High sensitivity C-reactive protein in asthma. *Eur Respir J* 2006;**27**:908-12.
 24. Szeffler SJ, Wenzel S, Brown R *et al*. Asthma outcomes: biomarkers. *J Allergy Clin Immunol* 2012;**129**:S9-23.
 25. Apostol GG, Jacobs DR, Tsai AW *et al*. Early life factors contribute to the decrease in lung function between ages 18 and 40: the Coronary Artery Risk Development in Young Adults study. *Am J Respir Crit Care Med* 2002;**166**: 166-72.
 26. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. *Am J Respir Crit Care Med* 1994;**150**: 629-34.
 27. Burrows B, Lebowitz MD, Barbee RA, Cline MG. Findings before diagnoses of asthma among the elderly in a longitudinal study of a general population sample. *J Allergy Clin Immunol* 1991;**88**:870-7.
 28. Cibella F, Cuttitta G, Bellia V *et al*. Lung function decline in bronchial asthma. *Chest* 2002;**122**:1944-8.
 29. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. *Chest* 2007;**132**:1882-9.
 30. Weiner P, Magadle R, Waizman J, Weiner M, Rabner M, Zamir D. Characteristics of asthma in the elderly. *Eur Respir J* 1998;**12**:564-8.
 31. Parker AL, McCool FD. Pulmonary function characteristics in patients with different patterns of methacholine airway hyperresponsiveness. *Chest* 2002;**121**:1818-23.
 32. Koh YI, Choi IS, Lim H. Airway responsiveness as a direct factor contributing to the dyspnoea perception in asthma. *Respir Med* 2001;**95**:464-70.
 33. Rasmussen F, Taylor DR, Flannery EM *et al*. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV₁/vital capacity ratio: a longitudinal population study from childhood to adulthood. *Am J Respir Crit Care Med* 2002;**165**:1480-8.
 34. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. *Eur J Respir Dis* 1987;**70**:171-9.
 35. Van Schayck CP, Dompeling E, Van Herwaarden CL, Wever AM, Van Weel C. Interacting effects of atopy and bronchial hyperresponsiveness on the annual decline in lung function and the exacerbation rate in asthma. *Am Rev Respir Dis* 1991;**144**:1297-301.
 36. Rijcken B, Schouten JP, Xu X, Rosner B, Weiss ST. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV₁. *Am J Respir Crit Care Med* 1995;**151**:1377-82.
 37. Postma DS, Lebowitz MD. Persistence and new onset of asthma and chronic bronchitis evaluated longitudinally in a community population sample of adults. *Arch Intern Med* 1995;**155**:1393-9.
 38. Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. *Eur Respir J* 1999;**14**:892-6.
 39. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. *Eur Respir J* 2007;**30**:452-6.
 40. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START Investigators Group. Severe exacerbations and decline in lung function in asthma. *Am J Respir Crit Care Med* 2009;**179**:19-24.
 41. Siroux V, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. *Eur Respir J* 2000;**15**:470-7.
 42. Boulet LP, Lemière C, Archambault F, Carrier G, Descary MC, Deschesnes F. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. *Chest* 2006;**129**:661-8.
 43. James AL, Palmer LJ, Kicic E *et al*. Decline in lung function in the Buselton Health Study: the effects of asthma and cigarette smoking. *Am J Respir Crit Care Med* 2005;**171**:109-14.
 44. Perret JL, Dharmage SC, Matheson MC *et al*. The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. *Am J Respir Crit Care Med* 2013;**187**:42-8.
 45. Ulrik CS. Outcome of asthma: longitudinal changes in lung function. *Eur Respir J* 1999;**13**:904-18.
 46. van Rensen EL, Sont JK, Evertse CE *et al*. Bronchial CD8 cell infiltrate and lung function decline in asthma. *Am J Respir Crit Care Med* 2005;**172**:837-41.
 47. Pasternack R, Huhtala H, Karjalainen J. Chlamydia (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. *J Allergy Clin Immunol* 2005;**116**: 1123-8.
 48. Imboden M, Bouzigon E, Curjuric I *et al*. Genome-wide association study of lung function decline in adults with and without asthma. *J Allergy Clin Immunol* 2012;**129**: 1218-28.

49. Jongepier H, Boezen HM, Dijkstra A *et al*. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. *Clin Exp Allergy* 2004;**34**:757-60.
50. Dijkstra A, Howard TD, Vonk JM *et al*. Estrogen receptor 1 polymorphisms are associated with airway hyperresponsiveness and lung function decline, particularly in female subjects with asthma. *J Allergy Clin Immunol* 2006;**117**:604-11.
51. Barton SJ, Koppelman GH, Vonk JM *et al*. PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline. *J Allergy Clin Immunol* 2009;**123**:1391-400.e17.
52. Koppelman GH, Sayers I. Evidence of a genetic contribution to lung function decline in asthma. *J Allergy Clin Immunol* 2011;**128**:479-84.
53. Li X, Hawkins GA, Ampleford EJ *et al*. Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. *J Allergy Clin Immunol* 2013;**132**:313-20.e15.
54. Pauwels RA, Pedersen S, Busse WW *et al*. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. *Lancet* 2003;**361**:1071-6.
55. Sidhu SS, Yuan S, Innes AL *et al*. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. *Proc Natl Acad Sci U S A* 2010;**107**:14170-5.
56. Takayama G, Arima K, Kanaji T *et al*. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. *J Allergy Clin Immunol* 2006;**118**:98-104.
57. Woodruff PG, Boushey HA, Dolganov GM *et al*. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. *Proc Natl Acad Sci U S A* 2007;**104**:15858-63.
58. Jia G, Erickson RW, Choy DF *et al*. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. *J Allergy Clin Immunol* 2012;**130**:647-54.
59. Corren J, Lemanske RF, Hanania NA *et al*. Leukotriene receptor antagonist treatment in adults with asthma. *N Engl J Med* 2011;**365**:1088-98.
60. Kanemitsu Y, Matsumoto H, Izuhara K *et al*. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. *J Allergy Clin Immunol* 2013;**132**:305-12.
61. Okamoto M, Hoshino T, Kitasato Y *et al*. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. *Eur Respir J* 2011;**37**:1119-27.
62. Murphy AC, Proeschal A, Brightling CE *et al*. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. *Thorax* 2012;**67**:751-3.
63. Shirai T, Furuhashi K, Suda T, Chida K. Relationship of the asthma control test with pulmonary function and exhaled nitric oxide. *Ann Allergy Asthma Immunol* 2008;**101**:608-13.
64. Lamblin C, Brichet A, Perez T, Darras J, Tonnel AB, Wallaert B. Long-term follow-up of pulmonary function in patients with nasal polyposis. *Am J Respir Crit Care Med* 2000;**161**:406-13.
65. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM; Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Care* 2004;**27**:752-7.
66. ten Brinke A, Sterk PJ, Masclee AA *et al*. Risk factors of frequent exacerbations in difficult-to-treat asthma. *Eur Respir J* 2005;**26**:812-8.